H yperphosphatemia in uremic patients is ass s sociated with metastatic calcification such as tumoral calcinosis and vascular calcificas s tion, and an increased cardiovascular mortality and morbidity. 1 To avoid hyperphosphatemiasrelated coms s plications, the use of oral phosphatesbinding agents is universal to reduce phosphate absorption in the gass s trointestinal tract. "Old generation" phosphate binders with aluminum or calciumsbased agents tend to cause neurological toxicity and exacerbation of calcium overs s loading and soft tissue or cardiovascular calcification, respectively. 2 The "new generation" of aluminum or calciumsfree phosphate binders has been shown to efs s fectively control serum phosphate concentration with the attenuation of cardiovascular and soft tissue calcis s fication.
Lanthanum carbonate (La 2 (CO 3 ) 3 ), is a novel cals s ciums and aluminumsfree phosphate binder for the treatment of hyperphosphatemia in ESRD patients. The element, lanthanum (La, atomic number 57, atomic weight 138.9) is a raresearth natural metal bes s longing to group 3B of the periodic table and causes radiopacities in the roentgenogram, as does barium (atomic number 56) (Figure 1 ). The halfslife of lanthas s num elimination from plasma is 53 hours though the plasma level is extremely low and elimination halfslife from bone is 2.0 to 3.6 years. 3 The affinity of lanthanum compound for phosphate is >97% and is more potent than calcium or magnesium, and similar to aluminum. 4 Lanthanum binds phosphate optimally at pH 3~5 and retains binding activity at pH 1~7. 5 It is virtually nons absorbed (0.00005%) and chelates dietary phosphate into insoluble lanthanum phosphate by ionized form. Lanthanum phosphate and carbonate in the gut may form numerous radiopaque spots on the abdominal xs ray, which is not reported with other phosphate binds s ers. 6, 7 These unexpected starry opacities disappear completely after the withdrawal of lanthanum carbonate. The patient continued lanthanum carbonate treatment because of no abdominal symptoms and improved pain. Due to this ras s diopaque feature, one can evaluate the compliance to this drug. Given the increasing usage of lanthanum carbonate in patients with ESRD, every physician must understand this typical benign radiopaque finding to avoid unnecess s sary examination and inappropriate management.
